A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer

Tumor Biology

Volumn 29, Issue 1, 2008, Pages 9-17

  Davelaar, Elvira M ^a   Van De Lande, Jonas ^a   Von Mensdorff Pouilly, Silvia ^a   Blankenstein, Marinus A ^a   Verheijen, René H M ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CA 125; CA 15 3; Cervical cancer; CYFRA 21 1; Prognosis; SCC antigen; Squamous cell carcinoma; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CYTOKERATIN 19; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 44349101723     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132566     Document Type: Article

References (31)

1. Moore DH: Cervical cancer. Obstet Gynecol 2006;107:1152-1161.
2. Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, Capocaccia R, EUROCARE Working Group: Trends in cervical cancer survival in Europe, 1983-1994: a population-based study. Gynecol Oncol 2007;105:609-619.
3. Delgado G, Bundy BN, Zaino R, Sevin BU, Creasman WT, Major F: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-357.
4. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB: Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol 2005;99:106-112.
5. Gadducci A, Tana R, Fanucchi A, Genazzani AR: Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol 2007;107(1 suppl 1):S23-S26.
6. Bon GG, von Mensdorff-Pouilly S, Kenemans P, Van Kamp GJ, Verstraeten RA, Hilgers J, Meijer S, Vermorken JB: Clinical and technical evaluation of ACS TM BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15.3 assays. Clin Chem 1997;43:585-593.
7. Scambia G, Benedetti Panici P, Foti E, Ferrandina G, Leone FPG, Marciano M, Mancuso S: Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Eur J Cancer 1996;32A:259-263.
8. Gaarenstroom KN, Bonfrer JM, Kenter GG, Korse CM, Hart AA, Trimbos JB, Helmerhorst TJ: Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 1995;76:807-813.
9. Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F: Lung cancer-associated keratin 19 fragments: development and biochemical characterization of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers 1994;9:75-81.
10. Kenemans P, Verstraeten AA, van Kamp GJ, von Mensdorff-Pouilly S: The second generation CA 125 assays. Ann Med 1995;27:107-113.
11. Cox DR: Regression models and life tables. J R Stat Soc 1972;B34:187-220.
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-24.
14. Roy M, Plate M: Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer. Am J Obstet Gynecol 1998;179:1491-1496.
15. Yessaian A, Magistris A, Burger RA, Monk BJ: Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol 2004;94:61-66.
16. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C: Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-540.
17. Morris M, Eifel JP, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med 1999;340:1137-1143.
18. Arbyn M, Raifu AO, Autier P, Ferlay J: Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1707-1715.
19. Åvall-Lundqvist EH, Sjövall K, Nilsson BR, Eneroth PHE: Prognostic significance of pre-treatment serum levels of squamous cell carcinoma antigen and CA125 in cervical carcinoma. Eur J Cancer 1992;28A:1695-1702.
20. Duk JM, Groenier KH, de Bruijn HWA, Hollema H, ten Hoor KA, van der Zee AGJ, Aalders JG: Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996;14:111-118.
21. Yuan CC, Wang PH, Ng HT, Tsai LC, Juang CM, Chiu LM: Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by stratification analysis. Eur J Gynaecol Oncol 2002;23:17-20.
22. Strauss H-G, Laban C, Lautenschläger C, Buchmann J, Schneider I, Koelbl H: SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur J Cancer 2002;38:1987-1991.
23. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torné A, Rovirosa A, Mellado B, Ordi J, Puig-Tintore LM, Alicarte J, Biete A, Iglesias J: Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol 2003;24:156-164.
24. Reesink-Peters N, van der Velden J, ten Hoor KA, Boezem HM, de Vries EGE, Schilthuis MS, Mourits MJE, Nijman HW, Aalders JG, Hollema H, Pras E, Duk JM, van der Zee AGJ: Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 2005;23:1455-1462.
25. Bolger BS, Dabbas M, Lopes A, Monaghan JM: Prognostic value of preoperative squamous cell carcinoma antigen levels in patients surgically treated for cervical carcinoma. Gynecol Oncol 1997;65:309-313.
26. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Hart AA, Van de Vijver MJ, Fleuren G-J, Trimbos JB: Can initial serum CYFRA 21-1, SCC antigen, and TPA levels in squamous cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 2000;77:164-170.
27. Bonfrer JMG, Gaarenstroom KN, Kenter GG, Korse CM, Hart AAM, Gallee MPW, Helmerhorst TJM, Kenemans P: Prognostic significance of serum fragments of cytokeratin 19 measured by CYFRA 21-1 in cervical cancer. Gynecol Oncol 1994;55:371-375.
28. Bonfrer JMG, Gaarenstroom KN, Korse CM, Van Bunningen BNFM, Kenemans P: Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res 1997;17:2329-2334.
29. Molina R, Filella X, Augé JM, Bosch E, Torné A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A: CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res 2005;25:1765-1772.
30. Takeda M, Sakuragi N, Okamoto K, Todo Y, Minobe S-I, Nomura E, Negishi H, Oikawa M, Yamamoto R, Fujimoto S: Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 2002;81:451-457.
31. Massuger LFAG, Koper NP, Thomas CMG, Dom KEL, Schijf CPT: Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA125 determinations. Gynecol Oncol 1997;64:473-476.